![]() |
|
|
Vol. 283, Issue 2, 824-832, 1997
Department of Clinical Pharmacology and Pharmacotherapy (M.D.,
B.v.d.B., C.v.B.) and
Department of Pulmonology (J.v.d.Z., M.B.),
Academic Medical Center, Amsterdam, The Netherlands
The kinetics of inhaled racemic formoterol and its effects on the size
of the early cutaneous reaction to intradermal injection of an
allergen, eosinopenia and hypokalemia were assessed by
pharmacokinetic-pharmacodynamic modeling. After inhalation of either
120 µg of formoterol or placebo, blood samples were taken and skin
tests were performed in seven healthy subjects. A two-compartment model
was needed to describe the observed formoterol plasma
concentration-time curves. To describe the observed biphasic
concentration, two absorption routes with different absorption rate
constants were incorporated in the model. These two phases were
explained by rapid absorption via the respiratory tract
together with a slower and delayed oral absorption. For the description
of the concentration-effect relations, an Emax (the maximum
obtainable effect) formula for competitive agonism, with an effect
compartment, had to be used. Fitting the wheal and flare, an apparent
diurnal variation had to be taken into account by incorporating in the
model rising base-line values. For the flare responses, influence of
the location on the forearm appeared to be operative. Systemic
formoterol absorbed via the oral route behaved
differently from the fraction absorbed via the lungs,
with EC50 (steady state concentration that gives 50% of
maximum effect) values for all three systemic effects being three times
lower after oral absorption than after absorption via
the respiratory tract. Pharmacodynamic parameters can probably only be
estimated quantitatively when the kinetics of the separate enantiomers
of formoterol can be taken into account.